Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 4/20 | 0.84 |
| ▸ | MALT1 | Q9UDY8 | 14/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117653 | 0.86 | MARS1 (0.65) | MARS1MALT1MEN1KMT2AL3MBTL1 | |
| SCHEMBL118666 | 0.77 | MARS1 (1.00) | MARS1L3MBTL1 | |
| SCHEMBL6345557 | 0.71 | MAPK9 (0.71) | MALT1 | |
| SCHEMBL5529688 | 0.69 | MARS1 (0.52) | MARS1MALT1MEN1KMT2ANFKB1 | |
| SCHEMBL116301 | 0.68 | MARS1 (1.00) | MARS1L3MBTL1 | |
| SCHEMBL14416565 | 0.68 | MARS1 (0.51) | MARS1MALT1MEN1KMT2A | |
| SCHEMBL27694757 | 0.68 | TDP1 (0.57) | MARS1MALT1MEN1KMT2AL3MBTL1 | |
| SCHEMBL24441094 | 0.67 | MALT1 (1.00) | MALT1MEN1KMT2ANFKB1NFKB2 | |
| SCHEMBL5523089 | 0.67 | CNR1 (0.53) | MARS1MALT1MEN1KMT2ANFKB1 | |
| SCHEMBL18353660 | 0.67 | MARS1 (0.59) | MARS1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885MALT1 1032/4885MEN1 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.